Trial
NCT02745145
Abituzumab in SSc-ILD
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Systemic Sclerosis-associated Interstitial Lung Disease
Intervention
Abituzumab 1500 mg
Why stopped
Difficulties experienced in identifying participants who meet the eligibility criteria of the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-18